Atypical post-finasteride syndrome: A pharmacological riddle

Area of Science:

• Pharmacology
• Endocrinology
• Dermatology

Background:

• Finasteride and dutasteride are 5-alpha reductase inhibitors used for benign prostatic hypertrophy (BPH) and androgenic alopecia (AGA).
• Finasteride selectively inhibits 5-alpha reductase Type II, while dutasteride inhibits both Type I and II.
• Dutasteride is FDA-approved for BPH, with off-label use in AGA, whereas finasteride is approved for both conditions.

Observation:

• Postfinasteride syndrome (PFS) is a recognized entity with variable symptoms.
• This report describes an unusual case of PFS in a patient treated with both dutasteride and finasteride for AGA.
• The patient presented with multisystemic involvement and irreversible symptoms.

Findings:

• The case illustrates an atypical presentation of PFS potentially linked to dutasteride and finasteride use.
• The observed symptoms were severe, affecting multiple organ systems.
• The condition appeared irreversible, underscoring the potential for long-term adverse effects.

Implications:

• This case highlights the need for increased awareness of atypical and severe PFS presentations.
• Further research into the mechanisms and long-term consequences of 5-alpha reductase inhibitor-induced syndromes is warranted.
• Clinicians should carefully consider the risks and benefits when prescribing these medications, especially for off-label uses like AGA.